Bartlett NL et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study. ASH 2022;Abstract 610.
Dickinson M et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. ASCO 2022;Abstract 7500.
Dickinson M et al. Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: Pivotal phase II expansion results. EHA 2022;Abstract S220.
Falchi L et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. ASCO 2022;Abstract 7524.
Kim TM et al. Odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) grade 1-3a: Results from a prespecified analysis of the pivotal phase II study ELM-2. ASH 2022;Abstract 949.
Kim WS et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study ELM-2. ASH 2022;Abstract 444.
Robak T et al. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers 2022;14(3):771. Abstract